Guggenheim raised the firm’s price target on DBV Technologies (DBVT) to $51 from $35 and keeps a Buy rating on the shares after the “highly positive” topline readout from the Phase 3 VITESSE study of the Viaskin peanut patch in children with peanut allergy. The firm is “very pleased” with the VITESSE results and looks forward to the continued development towards a commercial launch, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT: